There are currently 2866 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Recruiting
This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose administration in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) and immune thrombocytopenia (ITP).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/19/2025
Locations: Nerve and Muscle Center of Texas, Houston, Texas
Conditions: Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM), Immune-mediated Necrotizing Myopathy (IMNM), Immune Thrombocytopenia (ITP)
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Recruiting
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.
Gender:
FEMALE
Ages:
15 years and above
Trial Updated:
05/19/2025
Locations: Research Site, Houston, Texas
Conditions: Locally Advanced Cervical Cancer
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
Recruiting
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: HCA Houston Healthcare Medical Center, Houston, Texas +3 locations
Conditions: Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer
Recruiting
To learn if Cognitive Behavior Therapy (called CBT), combined with either Bright Light Therapy (called BLT), methylphenidate, and/or melatonin, can help improve sleep and other related symptoms such as fatigue, anxiety, and depression in cancer patients. This is an investigational study. In this study, BLT, Methylphenidate and Melatonin will be compared to their placebos.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Sleep, Fatigue, Anxiety, Cancer, Depression
A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer
Recruiting
The purpose of this study is to find out how many participants are interested in a surgical preventive procedure after watching an educational video. Before and after watching the video, participants will complete questionnaires in the clinic.
Gender:
FEMALE
Ages:
45 years and above
Trial Updated:
05/19/2025
Locations: MD Anderson Cancer Center (Data Collection Only), Houston, Texas
Conditions: Surgery
Primary Sclerosing Cholangitis in Children
Recruiting
Primary sclerosing cholangitis (PSC) is a rare liver disease that damages the liver's bile ducts. Bile ducts are tiny tubes that carry bile from the liver to the small intestine. Bile is a liquid produced by the liver that helps us absorb and use the nutrients in the food we eat. In people with PSC, the bile backs up into the liver and will damage it, causing scarring of the liver. The purposes of this study are to: * Collect medical and other data to learn more about PSC, how it progresses, a... Read More
Gender:
ALL
Ages:
Between 2 years and 25 years
Trial Updated:
05/19/2025
Locations: Texas Children's Hospital (Baylor College of Medicine), Houston, Texas
Conditions: Primary Sclerosing Cholangitis, Liver Diseases, Cholangitis, Sclerosing
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Recruiting
This phase I/II trial studies how well quizartinib, decitabine, and venetoclax work in treating participants with acute myeloid leukemia or high risk myelodysplastic syndrome that is untreated or has come back (relapsed). Quizartinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as decitabine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Recruiting
This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase. The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and maintenance therapy in subjects with moderately to severely active CD after inadequate response (no response, loss of response, or intolerance) to conventional therapies and/or advanced therapies. The primary objective for the 48-Week Extension Phase is to evaluate the sa... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/19/2025
Locations: Houston Methodist Hospital, Houston, Texas
Conditions: Moderately to Severely Active Crohn Disease
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
Recruiting
This is a phase 1, first in human, dose escalation study for safety and feasibility of multi-dose dendritic cell (DC) therapy for pancreatic ductal adenocarcinoma (PDAC) including adenosquamous carcinoma administered after surgical resection of PDAC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Baylor College of Medicine Medical Center - McNair Campus, Houston, Texas +2 locations
Conditions: Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenosquamous Carcinoma
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
Recruiting
This trial collects feedback from patients to develop a video game in improving the outcomes in stem cell transplant survivors. A video game may help to improve health behaviors for leukemia or lymphoma patients after stem cell transplant.
Gender:
ALL
Ages:
Between 15 years and 39 years
Trial Updated:
05/19/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Leukemia, Lymphoma
Immunization With BCG Vaccine to Prevent Tuberculosis Infection
Recruiting
The purpose of this research is to find out if a single dose of pre-travel vaccination with BCG can lessen tuberculosis (TB) infection by producing an immune response when given to adults traveling to countries with a high burden of TB. BCG will be compared with a placebo (an inactive vaccine). BCG (Japan) is used globally but is not approved for use in the United States, therefore it is considered experimental. Participants choosing to take part in this research study, will be randomly assigned... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/19/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Tuberculosis Infection
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
Recruiting
This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyopathy (HCM) caused by mutations in the MYBPC3 gene.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/19/2025
Locations: Houston Methodist Hospital, Houston, Texas
Conditions: Hypertrophic Cardiomyopathy